Our Mission
Current treatments for cancers like glioblastoma (GBM) may extend life by several months but are not curative and often have debilitating side effects. Investigational product Immune12, a marine-sourced complex biological, is currently being evaluated for its potential to be an effective, safe and easily delivered treatment for GBM and other challenging cancers. Pacific Marine Biotech (PMB) is a United States based company with a mission to bring this innovative product and its associated treatment method to the global health industry. If successful, we will realize our vision of
Changing the Way Cancer is Treated.
Press & Social
PMB’s Primary Area of Focus
PMB’s focus is on launching clinical trials for GBM and DIPG using its product, Immune12, a complex biologic compound derived from marine organisms.
GBM and DIPG are orphan diseases with no cure. Current treatments may extend life by several months but are not curative.
Upon diagnosis, patients face a grim reality with little to no hope for recovery. While existing standard-of-care treatments like radiation and chemotherapy may extend life by a few months, they fall significantly short of providing a cure. Moreover, the side effects associated with these treatments can be severe and debilitating, further compromising the quality of life for patients.
...and what this means to:
Patients & Caregivers
We are committed to completing our research, working with regulatory bodies like the FDA and TGA, to make advancements for patients and families—especially those facing serious illnesses such as glioblastoma.
Immune Precision
Derived from marine biologics, Immune-12 may help modulate immune responses, offering a more targeted and natural
HCPs
PMB’s focus is on launching clinical trials for GBM and DIPG using its product, Immune12, a complex biologic compound derived from marine organisms.
GBM and DIPG are orphan diseases with no cure. Current treatments may extend life by several months but are not curative.
Upon diagnosis, patients face a grim reality with little to no hope for recovery. While existing standard-of-care treatments like radiation and chemotherapy may extend life by a few months, they fall significantly short of providing a cure. Moreover, the side effects associated with these treatments can be severe and debilitating, further compromising the quality of life for patients.
Investors
PMB’s focus is on launching clinical trials for GBM and DIPG using its product, Immune12, a complex biologic compound derived from marine organisms.
GBM and DIPG are orphan diseases with no cure. Current treatments may extend life by several months but are not curative.
Upon diagnosis, patients face a grim reality with little to no hope for recovery. While existing standard-of-care treatments like radiation and chemotherapy may extend life by a few months, they fall significantly short of providing a cure. Moreover, the side effects associated with these treatments can be severe and debilitating, further compromising the quality of life for patients.